HRS-2162

Fujian Shengdi Pharmaceutical Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	HRS-2162
Sponsor	Fujian Shengdi Pharmaceutical Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Single Ascending Dose of HRS-2162 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HRS-2162 CI brief — competitive landscape report
HRS-2162 updates RSS · CI watch RSS
Fujian Shengdi Pharmaceutical Co., Ltd. portfolio CI